EUVIMEDEUVIMED entdecken
Fallbericht

Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months of therapy and the patient is still in complete remission after 3 years. A case report and iteraure review.

A Čermák, J Foukal, Z Řehák, Z Adam, M Keřkovský, L Hruška, M Borský, M Doubek, J Vlažný, Z Pavlovský, Z Chovancová, I Boichuk und 5 weitere

Klinicka onkologie · 2024

DOI: 10.48095/ccko2024354 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Klinicka onkologie, 2024. Verfasst von A Čermák und 16 weiteren Autor:innen. Hauptthemen laut MEDLINE: Retroperitoneal Fibrosis, Rituximab, Cyclophosphamide, Dexamethasone.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retroperitoneal FibrosisRituximabCyclophosphamideDexamethasoneFluorodeoxyglucose F18HumansMaleMiddle AgedDrug Therapy, CombinationPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

CyclophosphamideIgG4-related diseasecirculating plasmablastscyclophosphamideretroperitoneal fibrosisrituximab

Substanzen

RituximabCyclophosphamideDexamethasoneFluorodeoxyglucose F18

Zitieren

APA

Čermák, A., Foukal, J., Řehák, Z., Adam, Z., Keřkovský, M., Hruška, L., Borský, M., Doubek, M., Vlažný, J., Pavlovský, Z., Chovancová, Z., Boichuk, I., Štork, M., Pour, L., Koukalová, R., Tomíška, M., & Král, Z. (2024). Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months of therapy and the patient is still in complete remission after 3 years. A case report and iteraure review. Klinicka onkologie. https://doi.org/10.48095/ccko2024354

Vancouver

Čermák A, Foukal J, Řehák Z, Adam Z, Keřkovský M, Hruška L, et al. Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months of therapy and the patient is still in complete remission after 3 years. A case report and iteraure review. Klinicka onkologie. 2024. doi:10.48095/ccko2024354

BibTeX
@article{ermk2024,
  author = {Čermák, A and Foukal, J and Řehák, Z and Adam, Z and Keřkovský, M and Hruška, L and Borský, M and Doubek, M and Vlažný, J and Pavlovský, Z and Chovancová, Z and Boichuk, I and Štork, M and Pour, L and Koukalová, R and Tomíška, M and Král, Z},
  title = {Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months of therapy and the patient is still in complete remission after 3 years. A case report and iteraure review},
  journal = {Klinicka onkologie},
  year = {2024},
  doi = {10.48095/ccko2024354}
}
Kostenlos starten →